Long-term survival achieved by repeated administration of ramucirumab after drug holidays due to proteinuria in recurrent gastric cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-04-20

AUTHORS

Naoyuki Uehata, Keita Kouzu, Hironori Tsujimoto, Hidekazu Sugasawa, Kotaro Wakamatsu, Yoji Kishi, Hideki Ueno

ABSTRACT

BACKGROUND: The prognosis of recurrent and unresectable gastric cancer remains poor despite the development of multidisciplinary treatments. Ramucirumab (RAM) has been proven effective against unresectable or recurrent gastric cancer. However, its administration is often discontinued because of adverse events, including hypertension and proteinuria. We report a patient with recurrent gastric cancer involving the paraaortic lymph node (PALN), who achieved long-term survival after repeated RAM administration following long-term drug holidays due to proteinuria. CASE PRESENTATION: A 79-year-old woman was diagnosed with advanced gastric cancer (cT4aN2) with PALN metastasis. Seven courses of S-1 plus cisplatin (SP) achieved downstaging. A distal gastrectomy with D2 lymphadenectomy was performed as a conversion surgery. The pathological diagnosis was ypT3N2M0. The dissected PALN did not contain viable cancer cells. CT and positron emission tomography/CT scans revealed PALN recurrence 1 year after the surgery. S-1 plus oxaliplatin (SOX) therapy was initiated. The recurrent PALN enlarged after seven courses of SOX therapy. Paclitaxel (PTX) plus ramucirumab (RAM) therapy was initiated as second-line chemotherapy. After three courses of PTX plus RAM therapy, a partial response was observed. PTX was discontinued because of a hematological adverse event 3.5 months after PALN recurrence. Disease progression was not observed after six courses of RAM monotherapy. However, RAM caused proteinuria and was withdrawn for 7 weeks. The recurrent PALN was enlarged on CT, and RAM monotherapy was resumed at a reduced dose of 6 mg/kg. The lesion subsequently shrank, but 4 + proteinuria occurred after three courses of RAM monotherapy. Thus, RAM was discontinued. The patient had chemotherapy-free days for 14 months until the PALN was re-enlarged to 13 mm in size. The three administrations of RAM successfully controlled PALN metastasis and proteinuria for 3 years. CONCLUSION: In conclusion, even if RAM withdrawal led to disease progression, re-administration of RAM monotherapy while considering its side effects reduced the tumor size and provided long-term survival benefits. More... »

PAGES

97

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40792-021-01185-9

DOI

http://dx.doi.org/10.1186/s40792-021-01185-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1137313504

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33876326


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uehata", 
        "givenName": "Naoyuki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kouzu", 
        "givenName": "Keita", 
        "id": "sg:person.01006713465.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006713465.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsujimoto", 
        "givenName": "Hironori", 
        "id": "sg:person.01022371461.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022371461.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sugasawa", 
        "givenName": "Hidekazu", 
        "id": "sg:person.01357636001.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357636001.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wakamatsu", 
        "givenName": "Kotaro", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kishi", 
        "givenName": "Yoji", 
        "id": "sg:person.0651772025.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651772025.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ueno", 
        "givenName": "Hideki", 
        "id": "sg:person.01053200431.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053200431.41"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12882-018-1194-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111361376", 
          "https://doi.org/10.1186/s12882-018-1194-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10120-016-0622-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005167644", 
          "https://doi.org/10.1007/s10120-016-0622-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrclinonc.2009.94", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035657151", 
          "https://doi.org/10.1038/nrclinonc.2009.94"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-04-20", 
    "datePublishedReg": "2021-04-20", 
    "description": "BACKGROUND: The prognosis of recurrent and unresectable gastric cancer remains poor despite the development of multidisciplinary treatments. Ramucirumab (RAM) has been proven effective against unresectable or recurrent gastric cancer. However, its administration is often discontinued because of adverse events, including hypertension and proteinuria. We report a patient with recurrent gastric cancer involving the paraaortic lymph node (PALN), who achieved long-term survival after repeated RAM administration following long-term drug holidays due to proteinuria.\nCASE PRESENTATION: A 79-year-old woman was diagnosed with advanced gastric cancer (cT4aN2) with PALN metastasis. Seven courses of S-1 plus cisplatin (SP) achieved downstaging. A distal gastrectomy with D2 lymphadenectomy was performed as a conversion surgery. The pathological diagnosis was ypT3N2M0. The dissected PALN did not contain viable cancer cells. CT and positron emission tomography/CT scans revealed PALN recurrence 1 year after the surgery. S-1 plus oxaliplatin (SOX) therapy was initiated. The recurrent PALN enlarged after seven courses of SOX therapy. Paclitaxel (PTX) plus ramucirumab (RAM) therapy was initiated as second-line chemotherapy. After three courses of PTX plus RAM therapy, a partial response was observed. PTX was discontinued because of a hematological adverse event 3.5\u00a0months after PALN recurrence. Disease progression was not observed after six courses of RAM monotherapy. However, RAM caused proteinuria and was withdrawn for 7 weeks. The recurrent PALN was enlarged on CT, and RAM monotherapy was resumed at a reduced dose of 6\u00a0mg/kg. The lesion subsequently shrank, but 4\u2009+\u2009proteinuria occurred after three courses of RAM monotherapy. Thus, RAM was discontinued. The patient had chemotherapy-free days for 14\u00a0months until the PALN was re-enlarged to 13\u00a0mm in size. The three administrations of RAM successfully controlled PALN metastasis and proteinuria for 3 years.\nCONCLUSION: In conclusion, even if RAM withdrawal led to disease progression, re-administration of RAM monotherapy while considering its side effects reduced the tumor size and provided long-term survival benefits.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s40792-021-01185-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1052102", 
        "issn": [
          "2198-7793"
        ], 
        "name": "Surgical Case Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "paraaortic lymph nodes", 
      "recurrent gastric cancer", 
      "gastric cancer", 
      "long-term survival", 
      "drug holiday", 
      "PALN metastasis", 
      "disease progression", 
      "positron emission tomography/CT scan", 
      "long-term survival benefit", 
      "prognosis of recurrent", 
      "unresectable gastric cancer", 
      "second-line chemotherapy", 
      "courses of paclitaxel", 
      "advanced gastric cancer", 
      "viable cancer cells", 
      "recurrence 1 year", 
      "D2 lymphadenectomy", 
      "oxaliplatin therapy", 
      "SOX therapy", 
      "ramucirumab therapy", 
      "RAM therapy", 
      "PALN recurrence", 
      "distal gastrectomy", 
      "multidisciplinary treatment", 
      "adverse events", 
      "conversion surgery", 
      "partial response", 
      "survival benefit", 
      "lymph nodes", 
      "tumor size", 
      "pathological diagnosis", 
      "ramucirumab", 
      "proteinuria", 
      "CT scan", 
      "monotherapy", 
      "side effects", 
      "therapy", 
      "cancer", 
      "administration", 
      "paclitaxel", 
      "cancer cells", 
      "patients", 
      "surgery", 
      "metastasis", 
      "progression", 
      "months", 
      "CT", 
      "survival", 
      "course", 
      "gastrectomy", 
      "lymphadenectomy", 
      "hypertension", 
      "chemotherapy", 
      "prognosis", 
      "recurrence", 
      "lesions", 
      "years", 
      "recurrent", 
      "diagnosis", 
      "dose", 
      "cisplatin", 
      "weeks", 
      "women", 
      "scans", 
      "treatment", 
      "withdrawal", 
      "days", 
      "conclusion", 
      "cells", 
      "response", 
      "holidays", 
      "benefits", 
      "events", 
      "effect", 
      "development", 
      "size", 
      "nodes", 
      "RAM administration", 
      "long-term drug holidays", 
      "dissected PALN", 
      "emission tomography/CT scans", 
      "tomography/CT scans", 
      "PALN recurrence 1 year", 
      "recurrent PALN", 
      "hematological adverse event 3.5", 
      "adverse event 3.5", 
      "event 3.5", 
      "RAM monotherapy", 
      "chemotherapy-free days", 
      "administrations of RAM", 
      "RAM withdrawal"
    ], 
    "name": "Long-term survival achieved by repeated administration of ramucirumab after drug holidays due to proteinuria in recurrent gastric cancer", 
    "pagination": "97", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1137313504"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40792-021-01185-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33876326"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40792-021-01185-9", 
      "https://app.dimensions.ai/details/publication/pub.1137313504"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T19:02", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_910.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s40792-021-01185-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40792-021-01185-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40792-021-01185-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40792-021-01185-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40792-021-01185-9'


 

This table displays all metadata directly associated to this object as RDF triples.

204 TRIPLES      22 PREDICATES      120 URIs      109 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40792-021-01185-9 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N34588d580d5f48a6a3ac4f12707fd161
4 schema:citation sg:pub.10.1007/s10120-016-0622-4
5 sg:pub.10.1038/nrclinonc.2009.94
6 sg:pub.10.1186/s12882-018-1194-9
7 schema:datePublished 2021-04-20
8 schema:datePublishedReg 2021-04-20
9 schema:description BACKGROUND: The prognosis of recurrent and unresectable gastric cancer remains poor despite the development of multidisciplinary treatments. Ramucirumab (RAM) has been proven effective against unresectable or recurrent gastric cancer. However, its administration is often discontinued because of adverse events, including hypertension and proteinuria. We report a patient with recurrent gastric cancer involving the paraaortic lymph node (PALN), who achieved long-term survival after repeated RAM administration following long-term drug holidays due to proteinuria. CASE PRESENTATION: A 79-year-old woman was diagnosed with advanced gastric cancer (cT4aN2) with PALN metastasis. Seven courses of S-1 plus cisplatin (SP) achieved downstaging. A distal gastrectomy with D2 lymphadenectomy was performed as a conversion surgery. The pathological diagnosis was ypT3N2M0. The dissected PALN did not contain viable cancer cells. CT and positron emission tomography/CT scans revealed PALN recurrence 1 year after the surgery. S-1 plus oxaliplatin (SOX) therapy was initiated. The recurrent PALN enlarged after seven courses of SOX therapy. Paclitaxel (PTX) plus ramucirumab (RAM) therapy was initiated as second-line chemotherapy. After three courses of PTX plus RAM therapy, a partial response was observed. PTX was discontinued because of a hematological adverse event 3.5 months after PALN recurrence. Disease progression was not observed after six courses of RAM monotherapy. However, RAM caused proteinuria and was withdrawn for 7 weeks. The recurrent PALN was enlarged on CT, and RAM monotherapy was resumed at a reduced dose of 6 mg/kg. The lesion subsequently shrank, but 4 + proteinuria occurred after three courses of RAM monotherapy. Thus, RAM was discontinued. The patient had chemotherapy-free days for 14 months until the PALN was re-enlarged to 13 mm in size. The three administrations of RAM successfully controlled PALN metastasis and proteinuria for 3 years. CONCLUSION: In conclusion, even if RAM withdrawal led to disease progression, re-administration of RAM monotherapy while considering its side effects reduced the tumor size and provided long-term survival benefits.
10 schema:genre article
11 schema:inLanguage en
12 schema:isAccessibleForFree true
13 schema:isPartOf N3f93fa34908947bca9a96fff58db1f57
14 N93b9467e44ed4dcca0ff4320a05aaad8
15 sg:journal.1052102
16 schema:keywords CT
17 CT scan
18 D2 lymphadenectomy
19 PALN metastasis
20 PALN recurrence
21 PALN recurrence 1 year
22 RAM administration
23 RAM monotherapy
24 RAM therapy
25 RAM withdrawal
26 SOX therapy
27 administration
28 administrations of RAM
29 advanced gastric cancer
30 adverse event 3.5
31 adverse events
32 benefits
33 cancer
34 cancer cells
35 cells
36 chemotherapy
37 chemotherapy-free days
38 cisplatin
39 conclusion
40 conversion surgery
41 course
42 courses of paclitaxel
43 days
44 development
45 diagnosis
46 disease progression
47 dissected PALN
48 distal gastrectomy
49 dose
50 drug holiday
51 effect
52 emission tomography/CT scans
53 event 3.5
54 events
55 gastrectomy
56 gastric cancer
57 hematological adverse event 3.5
58 holidays
59 hypertension
60 lesions
61 long-term drug holidays
62 long-term survival
63 long-term survival benefit
64 lymph nodes
65 lymphadenectomy
66 metastasis
67 monotherapy
68 months
69 multidisciplinary treatment
70 nodes
71 oxaliplatin therapy
72 paclitaxel
73 paraaortic lymph nodes
74 partial response
75 pathological diagnosis
76 patients
77 positron emission tomography/CT scan
78 prognosis
79 prognosis of recurrent
80 progression
81 proteinuria
82 ramucirumab
83 ramucirumab therapy
84 recurrence
85 recurrence 1 year
86 recurrent
87 recurrent PALN
88 recurrent gastric cancer
89 response
90 scans
91 second-line chemotherapy
92 side effects
93 size
94 surgery
95 survival
96 survival benefit
97 therapy
98 tomography/CT scans
99 treatment
100 tumor size
101 unresectable gastric cancer
102 viable cancer cells
103 weeks
104 withdrawal
105 women
106 years
107 schema:name Long-term survival achieved by repeated administration of ramucirumab after drug holidays due to proteinuria in recurrent gastric cancer
108 schema:pagination 97
109 schema:productId N0c9f1ff6d38149d897e21584c9e0c881
110 N6f75fbe0d4654521b0dddfa25a72c808
111 N7646fb9376864482b1ef0346459a7c6a
112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137313504
113 https://doi.org/10.1186/s40792-021-01185-9
114 schema:sdDatePublished 2022-01-01T19:02
115 schema:sdLicense https://scigraph.springernature.com/explorer/license/
116 schema:sdPublisher N97071dad1cf449168ee44f5618cec537
117 schema:url https://doi.org/10.1186/s40792-021-01185-9
118 sgo:license sg:explorer/license/
119 sgo:sdDataset articles
120 rdf:type schema:ScholarlyArticle
121 N0c9f1ff6d38149d897e21584c9e0c881 schema:name doi
122 schema:value 10.1186/s40792-021-01185-9
123 rdf:type schema:PropertyValue
124 N34588d580d5f48a6a3ac4f12707fd161 rdf:first N83d567879d024b998ae3e17a81309015
125 rdf:rest N525d024ef76a4d159ffce7a64e131201
126 N382d8f33157c47c49d20e8d835096355 schema:affiliation grid-institutes:grid.416614.0
127 schema:familyName Wakamatsu
128 schema:givenName Kotaro
129 rdf:type schema:Person
130 N3f93fa34908947bca9a96fff58db1f57 schema:issueNumber 1
131 rdf:type schema:PublicationIssue
132 N525d024ef76a4d159ffce7a64e131201 rdf:first sg:person.01006713465.24
133 rdf:rest Nb394459b332d4dba86d837ca5a125086
134 N6d7f4ffa02324af3ae30ed3bd5d0d311 rdf:first sg:person.01053200431.41
135 rdf:rest rdf:nil
136 N6f75fbe0d4654521b0dddfa25a72c808 schema:name dimensions_id
137 schema:value pub.1137313504
138 rdf:type schema:PropertyValue
139 N7646fb9376864482b1ef0346459a7c6a schema:name pubmed_id
140 schema:value 33876326
141 rdf:type schema:PropertyValue
142 N83d567879d024b998ae3e17a81309015 schema:affiliation grid-institutes:grid.416614.0
143 schema:familyName Uehata
144 schema:givenName Naoyuki
145 rdf:type schema:Person
146 N93b9467e44ed4dcca0ff4320a05aaad8 schema:volumeNumber 7
147 rdf:type schema:PublicationVolume
148 N97071dad1cf449168ee44f5618cec537 schema:name Springer Nature - SN SciGraph project
149 rdf:type schema:Organization
150 N9ca17a4c19c148d3b8f3d682289315d4 rdf:first sg:person.01357636001.44
151 rdf:rest Nea6e7aa1677743668dfe0d6582d5feea
152 Nb394459b332d4dba86d837ca5a125086 rdf:first sg:person.01022371461.19
153 rdf:rest N9ca17a4c19c148d3b8f3d682289315d4
154 Nea6e7aa1677743668dfe0d6582d5feea rdf:first N382d8f33157c47c49d20e8d835096355
155 rdf:rest Nefaef3c645024f1d8427cf9c78d5ffeb
156 Nefaef3c645024f1d8427cf9c78d5ffeb rdf:first sg:person.0651772025.08
157 rdf:rest N6d7f4ffa02324af3ae30ed3bd5d0d311
158 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
159 schema:name Medical and Health Sciences
160 rdf:type schema:DefinedTerm
161 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
162 schema:name Oncology and Carcinogenesis
163 rdf:type schema:DefinedTerm
164 sg:journal.1052102 schema:issn 2198-7793
165 schema:name Surgical Case Reports
166 schema:publisher Springer Nature
167 rdf:type schema:Periodical
168 sg:person.01006713465.24 schema:affiliation grid-institutes:grid.416614.0
169 schema:familyName Kouzu
170 schema:givenName Keita
171 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006713465.24
172 rdf:type schema:Person
173 sg:person.01022371461.19 schema:affiliation grid-institutes:grid.416614.0
174 schema:familyName Tsujimoto
175 schema:givenName Hironori
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022371461.19
177 rdf:type schema:Person
178 sg:person.01053200431.41 schema:affiliation grid-institutes:grid.416614.0
179 schema:familyName Ueno
180 schema:givenName Hideki
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053200431.41
182 rdf:type schema:Person
183 sg:person.01357636001.44 schema:affiliation grid-institutes:grid.416614.0
184 schema:familyName Sugasawa
185 schema:givenName Hidekazu
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357636001.44
187 rdf:type schema:Person
188 sg:person.0651772025.08 schema:affiliation grid-institutes:grid.416614.0
189 schema:familyName Kishi
190 schema:givenName Yoji
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651772025.08
192 rdf:type schema:Person
193 sg:pub.10.1007/s10120-016-0622-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005167644
194 https://doi.org/10.1007/s10120-016-0622-4
195 rdf:type schema:CreativeWork
196 sg:pub.10.1038/nrclinonc.2009.94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035657151
197 https://doi.org/10.1038/nrclinonc.2009.94
198 rdf:type schema:CreativeWork
199 sg:pub.10.1186/s12882-018-1194-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111361376
200 https://doi.org/10.1186/s12882-018-1194-9
201 rdf:type schema:CreativeWork
202 grid-institutes:grid.416614.0 schema:alternateName Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan
203 schema:name Department of Surgery, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama 359-8513 Japan
204 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...